Los Angeles Times Profiles Success of Pharmaceutical Company Gilead, Maker of Viread
The Los Angeles Times today profiles pharmaceutical company Gilead Sciences and its CEO John Martin. Gilead, which manufactures Viread -- the fifth best-selling antiretroviral drug -- this month is launching a second antiretroviral drug, Emtriva, and is developing a once-daily combination pill to compete with industry leader GlaxoSmithKline's top-selling Combivir. According to the Times, Gilead owes much of its success to Martin's personal approach, which includes meeting with physicians who treat HIV/AIDS patients and "getting to know his customers: people infected with HIV" (Gellene, Los Angeles Times, 7/31). The complete article is available online.This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.